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Background.Dilationofmalignantstricturesinendoscopicultrasound(EUS)stagingofesophagealcancerissafe,butnodataexists
regardingthesubsequentdevelopmentofmetastases.Aim.Comparetheratesofmetastasesinesophagealcancerpatientsundergo-
ingEUS staging who require esophageal dilation inorder to pass the echoendoscope versus those who do not.Methods.W er evi e w -
ed consecutive patients referred for EUS staging of esophageal cancer. We evaluated whether dilation was necessary in order to pass
the echoendoscope, and for the subsequent development of metastases after EUS at various time intervals. Results. Among all pa-
tientswithsimilarstage(locallyadvanceddisease,deﬁnedasT3,N0,M0orT1-3,N1,M0),therewasnodiﬀerencebetweenthedil-
ated and nondilated groups in the rates of metastases at 3 months (14% versus 10%), P = 1.0, 6 months (28% versus 20%), P =
0.69, 12 months (43% versus 40%), P = 1.0, or ever during a mean followup of 15 months (71% versus 55%), P = 0.48. Con-
clusions. Dilation of malignant strictures for EUS staging of esophageal cancer does not appear to lead to higher rates of distant
metastases.
1.Introduction
Endoscopicultrasound(EUS)isanimportantpartofstaging
for esophageal cancer. It provides key information regarding
local tumor invasion, locoregional, and celiac lymph node
involvement. This information is essential to guide future
treatmentdecisions [1–9]. Oftena malignant strictureis pre-
sent that prohibits passage of the echoendoscope for com-
plete EUS staging. Earlier studies showed that dilating these
malignant strictures led to high complication rates [1, 10].
More recently, the safety of dilating malignant strictures for
passage of an echoendoscope for esophageal cancer staging
has been well established [2–4, 11]. Safety data in previous
studies primarily focused on rates of perforation. Currently
there are no data available on whether dilating malignant
strictures may precipitate metastatic spread of cancer.
At our institution, it was noted by our thoracic surgery
and oncology section that there were a high number of dis-
tant metastases in unusual locations shortly after surgery in
patients who had been dilated at the time of pretreatment
EUS staging. This led to a request by the thoracic surgery
section to limit dilation for the performance of EUS in the
staging of esophageal cancer patients.
Numerous reports of iatrogenic periprocedural spread of
cancer cells in many other procedures exist, including seed-
ing needle tracts in breast biopsies [12–14], diagnostic and
therapeutic procedures for hepatocellular carcinoma [15–
17], cutaneous seeding in laparoscopic cholecystectomy [18–
21], and seeding tracts with ﬁne needle aspiration (FNA) in
pancreatic, esophageal, and thyroid lesions [22–26]. It is also
well known that dilation of esophageal strictures carries a
high rate of transient bacteremia [27–30], presumably
through the breakdown of tissue planes and bacteria seeding
thebloodstream.Intheory,asimilarmechanismcouldoccur
with cancer cells seeding the bloodstream during dilation of
a malignant stricture, but this has not been previously docu-
mentedornoted.Thegoalofourstudyistoascertainifdilat-
ing malignant strictures in EUS esophageal cancer staging
lead to higher rates of metastases.2 Diagnostic and Therapeutic Endoscopy
2. Methods
Our institution uses a multimodality staging regimen for
esophageal cancer including EUS, CT scan, positron emis-
sion tomography (PET) scan, or combined CT-PET scan.
There was no predetermined order of the various staging
tests. We reviewed 55 consecutive patients referred for EUS
for the purpose of staging esophageal cancer. All patients had
biopsy-proven esophageal cancer. EUS was performed by 3
endoscopic ultrasonographers (D. V. Gopal, T. J. Frick, and
P. R. Pfau) with experience ranging from 5 to 10 years with
an average of 200EUS exams per year per endoscopist, using
an Olympus GF-UM130 or GF-UM160 radial array echoen-
d o s c o p e( O l y m p u sA m e r i c a ,M e l v i l l e ,N Y ,U S A )w i t hb o t h
7.5and12.0mHzfrequencies.Malignantstrictureswereonly
dilated if the stricture prevented passage of the echoendo-
scope. Dilation was performed sequentially with either wire-
guideddilationorathrough-the-scopeballoon.Nostrictures
were dilated beyond 15mm. EUS staging was done immedi-
ately after dilation using the American Joint Committee on
Cancer (AJCC) Tumor, Node, Metastasis (TNM) staging sys-
tem, 6th edition.
Patients’ electronic medical records were reviewed to ob-
tain all data. We collected data on the patients age, gender,
histology of cancer, location of malignant stricture (cervical
esophagus, thoracic esophagus, or gastroesophageal junc-
tion) if dilation was required to pass the echoendoscope,
TNM stage at the time of EUS, and whether or not distant
metastases had been identiﬁed at certain time intervals—0
(the time of original EUS staging), 1, 3, 6, and 12 months
following EUS, or at any time beyond 12 months if applica-
ble. Survival data was also collected using the Social Security
DeathIndex.Patientswhohadevidenceofdistantmetastases
onthepretreatmentstagingwerenotincludedintheanalysis.
Ascertainment of the presence of distant metastases at the
chosen time intervals was done by reviewing all imaging
studies and clinic notes through the given time interval on
each patient. This study was approved by the University of
Wisconsin Health Sciences Institutional Review Board.
Twogroupsofpatientswerecompared,thosewhorequir-
eddilationinordertopasstheechoendoscopeandthosewho
didnot.Patientswithlocallyadvanceddisease(deﬁnedasT3,
N0, M0 or T1-3, N1, M0) were identiﬁed in both the dilated
andnondilatedgroupandcomparedwitheachotherinorder
toattempttomatchthepatientsinthetwogroupsforsimilar
stage at the time of EUS.
Statistical analysis comparing the dilated group and non-
dilated group was performed with Chi-square test or Fisher’s
e x a c tt e s tw h e r ea p p r o p r i a t e .
3. Results
55 consecutive patients were identiﬁed. 23 patients required
dilation in order to pass the echoendoscope, 32 did not. The
echoendoscope was successfully passed through the malig-
nant stricture following dilation allowing full staging in 21 of
the 23 patients in the dilated group. There was no diﬀerence
between the two groups with respect to age, sex, location of
Table 1: Demographics of patients with esophageal cancer who did
and did not undergo dilation at the time of staging EUS.
Dilated
group
Nondilated
group P value
Total patients 23 32
Men 18 29 0.26
Women 5 3 0.26
Mean age 63 64
Adenocarcinoma 16 27 0.21
Squamous cell carcinoma 7 5 0.21
Cervical esophagus
stricture 2 2 0.99
Thoracic esophagus
stricture 61 0 0 . 7 7
Gastroesophageal junction
stricture 15 20 1.0
Metastases present at time
of EUS 9 6 0.13
Locally advanced disease at
time of EUS 14 20 1.0
stricture,orhistologyofcancer(Table 1).Therewerenopro-
cedure-related complications in either group.
15 of the 55 patients had distant metastases present at the
time of EUS, 9 in the dilated group and 6 in the nondilated
group (P = 0.13). In these 15 patients, EUS was done on the
same day or within the same week as the CT or PET that det-
ected the distant metastases. The remaining 40 patients had
no distant metastases at the time of the pretreatment staging
EUS. Of these 40 remaining patients, 14 required dilation at
the time of the staging EUS and 26 did not undergo dilation
atthetimeofstagingEUS.These40patientsformedthebasis
for the study’s comparison.
Of these 40 patients who had no evidence of metastatic
disease at the time of original staging, 10 of 14 (71%) in the
dilated group and 11 of 26 (46%) in the nondilated group
went on to develop metastases at any point during a mean
followup of 20 months (range 1–125) (P = 0.19) (Figure 1).
Metastaseswere detected at a median of 10 months (range 1–
54) after EUS in the dilated group and 10 months after EUS
inthenondilatedgroup(range1–125).Metastaseswereiden-
tiﬁed in a variety of locations in both the nondilated group
and the dilated group (Table 2).
Patients from the dilated and nondilated groups were
further compared to account for similar stage at the time of
EUS. All 14 patients in the dilated group and 20 out of 26 pa-
tients in the nondilated group had locally advanced disease
(deﬁned as T3, N0, M0 or T1-3, N1, M0). Excluding all pa-
tients withdistant metastasesatinitial staging,theexactdila-
t e dg r o u ps t a g e sw e r ea sf o l l o w s :T 3 N 1( N = 8), T2N1
(N = 1), and T3N0 (N = 5); the exact nondilated group
stages were as follows: T3N1 (N = 8), T2N1 (N = 5), T1N1
(N = 1), T3N0 (N = 6), T2N0 (N = 1), and T1N0 (N = 5).
Among these patients with locally advanced disease, the re-
sults were as follows: at both 1 and 3 months after EUS, 2 ofDiagnostic and Therapeutic Endoscopy 3
Table 2: Location of metastases by time from staging EUS in patients who did and did not undergo dilation at the time of staging EUS.
Dilated group Nondilated group
Location of metastases detected at <6 months (total number of
occurrences)
4 patients
Mediastinal lymph nodes (2)
Lungs (1)
Pleural eﬀusion (1)
Axillary lymph nodes (1)
Adrenal gland (1)
Gastric lymph nodes (1)
4 patients
Liver (2)
Peritoneum (2)
Back (1)
Location of metastases detected at 6–12 months (total number of
occurrences)
2 patients
Recurrence at GE junction (2)
Diﬀuse bony metastases (1)
Mediastinal lymph nodes (1)
5 patients
Liver (3)
Lungs (2)
Pleural eﬀusion (2)
Peritoneum (1)
Recurrence at GE junction (1)
Location of metastases detected at >12 months (total number of
occurrences)
4 patients
Recurrence at GE junction (1)
Axillary lymph nodes (1)
Cervical lymph nodes (1)
Neck (1)
Mediastinum (1)
3 patients
Recurrence at GE junction (1)
Lungs (1)
Abdominal mass (1)
Median time to detection of metastases (range) 10 months
(1–54 months)
10 months
(1–125 months)
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Figure1:Developmentofmetastasesatanytimeduringameanfol-
lowup of 20 months among all patients without metastases present
at the time of staging EUS.
14 (14%) in the dilated group had metastases present com-
pared to 2 of 20 (10%) in the nondilated group (P = 1.0);
at6monthsafterEUS,4of14(28%)inthedilatedgroupand
4of20(20%)inthenondilatedgrouphadmetastasespresent
(P = 0.69);at12monthsafterEUS,6of14(43%)inthedila-
ted group and 8 of 20 (40%) in the nondilated group had
metastases present (P = 1.0); 10 of 14 (71%) in the dilated
groupversus11of20(55%)inthenondilatedgroupwenton
to develop metastases at any time during a mean followup of
20 months (P = 0.48) (Figure 2).
Five-year survival data among all patients, regardless of
initial stage, reveal that 1 of 22 patients (4%) in the dilated
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Figure 2: Development of metastases at various time intervals after
EUS among patients with similar staging-locally advanced disease.
group was alive at 5-years, compared to 6 of 32 (19%) in the
nondilated group (P = 0.22). When those with metastases
presentatinitialstagingareexcluded,the5-yearsurvivaldata
is 1 of 14 (7%) in the dilated group, compared to 6 of 26
(23%)inthenondilatedgroup(P = 0.39).Amongthosewho
had locally advanced disease, the 5-year survival rate is 1 of
14 (7%) in the dilated group, compared to 1 of 20 (5%) in
the nondilated group (P = 1.0).
4. Discussion
EUS is an essential part of a comprehensive staging workup
for esophageal cancer and, when used appropriately in con-
junction with CT and/or PET scan, is generally considered4 Diagnostic and Therapeutic Endoscopy
the most accurate tool for staging [31]. Further, one of the
most important parts of EUS in staging esophageal cancer
is to ascertain the presence of celiac node involvement [32].
T h ee c h o e n d o s c o p en e e d st ob ea b l et op a s st h em a l i g n a n t
stricture in order to provide celiac node assessment. The
need for dilating a malignant stricture in order to pass the
echoendoscope is reported to be 10–38% [1–4, 7, 10, 11].
Thisemphasizestheimportanceofdilationincompletingac-
curate and comprehensive EUS staging that includes celiac
node assessment. Without dilation, these are patients that
would have suboptimal staging, which in turn can negatively
aﬀect treatment decisions.
Early studies concludedthat dilating malignant strictures
for the purposes of EUS staging of esophageal cancer was
dangerous, leading to unacceptably high rates of perforation
[1, 10]. More recent studies have refuted this and conﬁrmed
that dilating with smaller diameter Savary or through-the-
scope dilators, one can safely dilate malignant esophageal
strictures in order to complete EUS staging [2–4, 11].
These previous safety studies focused on perforation
rates in dilating malignant esophageal strictures. No studies
to date report any relationship between dilating malignant
strictures and the subsequent development of metastases. It
is well established that dilating esophageal strictures carries
a relatively high rate of transient bacteremia [27–30], pre-
sumably through the breakdown of tissue planes allowing
direct seeding of bacteria into the blood stream. One could
postulate that a similar mechanism could lead to cancer
cells seeding the bloodstream during dilation of a malignant
stricture, but there are no data to support this theory. This
theory was considered at our institution because of the ob-
servation of the rapid development of metastases in unusual
locations for a number of patients who had dilation of their
malignant strictures for EUS staging as part of their other-
wise negative pretreatment staging. Besides the analogy to
bacteremia during dilation as stated above, the possibility of
malignant spread may also be supported by reports of iatro-
genic periprocedural spread of tumor cells being well des-
cribedinotherprocedures,includingseedingneedletractsin
breast biopsies [12–14], diagnostic and therapeutic proce-
dures for hepatocellular carcinoma [15–17], cutaneous seed-
ing in laparoscopic cholecystectomy [18–21], and seeding
tracts with FNA in pancreatic, esophageal, and thyroid le-
sions [22–26].
Malignant cells have been noted in the blood stream after
various invasive procedures. Prostate cells, both benign and
malignant, have been isolated in the circulation following
transrectal prostate biopsy and transurethral resection of the
prostate[33].Furthermore,iatrogenicperiproceduralspread
of tumor cells directly into the bloodstream has been docu-
mented following percutaneous ethanol injection and trans-
arterial chemoembolization in primary liver cancer [34].
We did ﬁnd that among all patients (not matched for
similarstageatthetimeofEUS),thosewhorequireddilation
had a trend towards an overall higher rate of metastases at
any time during followup (71% versus 46%) (Figure 1).
However, this is not completely unexpected as those patients
with higher-grade strictures who required dilation generally
have more advanced disease [1, 2, 7, 8, 10], and therefore
the need for dilation may be a marker for more advanced or
aggressive disease. Thus, these patients may be more likely to
develop metastases at an earlier time regardless of dilation.
Because of this observation, we evaluated patients in the
dilated and nondilated groups to match those with similar
staging—locally advanced disease. When these groups were
analyzed, we saw no diﬀerence in the rates of metastases at
anytimeintervalstudied(Figure 2).Furthermore,thereisno
distinct pattern of metastatic spread unique to either group,
andnodistinctpatternoflocationofmetastasesbasedonthe
time frame they were detected. There is also no diﬀerence in
the median time to detection of metastases in either group
(Table 2).
Survival data show a nonsigniﬁcant trend towards lower
survival in the dilated group when we look at all patients re-
gardless of initial staging. A similar nonsigniﬁcant trend is
also seen among those without distant metastases at initial
staging. However, when the dilated and nondilated groups
werematchedforsimilarinitialstaging,locallyadvanceddis-
ease, ﬁve-year survival rates were similar.
Thepossibilityremainsthatdilationresultsinseedingthe
bloodstreamandmetastaticspreadofdiseaseinasmallnum-
ber of cases. However, this theory has not been proven in
anypreviousmodelorstudyinthisparticularclinicalsetting.
While limited by the total number of patients, our study ap-
pears to refute that dilation of malignant strictures leads to
increased rates of metastases. A more likely explanation is
simply that the cases of early metastases in each group repre-
sent metastases that were present but not detectable at the
time of initial staging.
Our study was limited by a small sample size, retrospec-
tive nature of the study, and being a single-center experience.
The small sample size makes it diﬃcult to draw any deﬁni-
tive conclusions; however, our study provides valuable infor-
mation about the natural progression of metastases in pa-
tients who undergo EUS for staging of esophageal cancer.
EUS provides the most accurate locoregional staging for
esophageal cancer, and dilation may often be necessary to
complete EUS staging. Dilating malignant strictures in order
to complete EUS staging does not clearly lead to a higher rate
of metastases.
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